Profluent closed a $106 million financing round led by Altimeter Capital and Bezos Expeditions to expand large‑scale AI models for protein design across therapeutics, agriculture and biomanufacturing. The company says its Protein Atlas contains more than 115 billion protein entries and is partnering with industrial players to commercialize bespoke enzymes and antibodies. Investors positioned the round as a push to move computational protein design from lab proof‑of‑concept to industrial throughput. Profluent described partnerships with Revvity and Integrated DNA Technologies and plans to invest proceeds in model scale‑up and wet‑lab validation pipelines. The funding underscores continued investor appetite for generative AI applied to biology and follows a wave of large rounds for AI‑driven protein and genomics startups.